KR20230148156A - 비알코올성 지방간 질병 및 관련 질병 또는 장애를치료 또는 개선하기 위한 화합물, 조성물, 및 방법 - Google Patents

비알코올성 지방간 질병 및 관련 질병 또는 장애를치료 또는 개선하기 위한 화합물, 조성물, 및 방법 Download PDF

Info

Publication number
KR20230148156A
KR20230148156A KR1020237027597A KR20237027597A KR20230148156A KR 20230148156 A KR20230148156 A KR 20230148156A KR 1020237027597 A KR1020237027597 A KR 1020237027597A KR 20237027597 A KR20237027597 A KR 20237027597A KR 20230148156 A KR20230148156 A KR 20230148156A
Authority
KR
South Korea
Prior art keywords
subject
sigma1
expression
sigmar1
nash
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237027597A
Other languages
English (en)
Korean (ko)
Inventor
펠릭스 진현 김
Original Assignee
토마스 제퍼슨 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 토마스 제퍼슨 유니버시티 filed Critical 토마스 제퍼슨 유니버시티
Publication of KR20230148156A publication Critical patent/KR20230148156A/ko
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/08Hepato-biliairy disorders other than hepatitis
    • G01N2800/085Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
KR1020237027597A 2021-01-15 2022-01-14 비알코올성 지방간 질병 및 관련 질병 또는 장애를치료 또는 개선하기 위한 화합물, 조성물, 및 방법 Pending KR20230148156A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163137915P 2021-01-15 2021-01-15
US63/137,915 2021-01-15
PCT/US2022/012516 WO2022155471A1 (en) 2021-01-15 2022-01-14 Compounds, compositions, and methods for treating or ameliorating nonalcoholic fatty liver disease and related diseases or disorders

Publications (1)

Publication Number Publication Date
KR20230148156A true KR20230148156A (ko) 2023-10-24

Family

ID=82448695

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237027597A Pending KR20230148156A (ko) 2021-01-15 2022-01-14 비알코올성 지방간 질병 및 관련 질병 또는 장애를치료 또는 개선하기 위한 화합물, 조성물, 및 방법

Country Status (6)

Country Link
US (1) US20240307325A1 (https=)
EP (1) EP4277898A4 (https=)
JP (1) JP2024504632A (https=)
KR (1) KR20230148156A (https=)
CA (1) CA3204756A1 (https=)
WO (1) WO2022155471A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116942821A (zh) * 2023-06-02 2023-10-27 深圳市第二人民医院(深圳市转化医学研究院) Sigmar1基因抑制剂在制备治疗或预防脂肪肝病的药物中的应用
WO2025194019A1 (en) * 2024-03-14 2025-09-18 Flagship Pioneering Innovations Vii, Llc Methods for treating liver fibrosis and non-alcoholic fatty liver disease
WO2026057679A1 (en) * 2024-09-11 2026-03-19 Institut National de la Santé et de la Recherche Médicale Inhibitor of rab30 for use in a method of treatment of metabolic dysfunction-associated steatotic liver disease (masld)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130142861A1 (en) * 2011-12-05 2013-06-06 National Yang Ming University Compositions And Method For Detecting And Treating Abnormal Liver Homeostasis And Hepatocarcinogenesis
WO2014015157A2 (en) * 2012-07-19 2014-01-23 Philadelphia Health & Education Corporation Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
WO2018112122A1 (en) * 2016-12-16 2018-06-21 Drexel University Methods of identifying and treating tumors with sigma1 inhibitors
EP3745862B1 (en) * 2018-01-31 2024-06-26 Mayo Foundation for Medical Education and Research D1 dopamine receptor agonists for treating fibrotic pathologies
WO2020112846A1 (en) * 2018-11-27 2020-06-04 Northwestern University Small molecule modulators of sigma-1 and sigma-2 receptors and uses thereof

Also Published As

Publication number Publication date
CA3204756A1 (en) 2022-07-21
EP4277898A4 (en) 2024-12-11
EP4277898A1 (en) 2023-11-22
WO2022155471A1 (en) 2022-07-21
JP2024504632A (ja) 2024-02-01
US20240307325A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
AU2020216186C1 (en) Oligonucleotide compositions and methods thereof
US10159670B2 (en) Methods of diagnosing and treating motor neuron diseases and other cellular stress-related diseases
KR102638276B1 (ko) 인트론 잔류의 감소
JP5535076B2 (ja) 肝臓癌を治療するための標的化ミクロrna
KR20230148156A (ko) 비알코올성 지방간 질병 및 관련 질병 또는 장애를치료 또는 개선하기 위한 화합물, 조성물, 및 방법
KR20190027373A (ko) 유전적 장애 치료를 위한, 특징이 개선된, 비사이클릭 스캐폴드 모이어티를 포함하는 프리-mrna 스플라이스 스위칭 또는 조정 올리고뉴클레오티드
US12077527B2 (en) Compositions and methods for inhibiting ACSS2
KR20140033062A (ko) 마이크로rna 화합물 및 mir-21 활성 조절 방법
CN118369427A (zh) 肝外递送irna组合物及其使用方法
US20220064642A1 (en) Oligomeric nucleic acid molecule and application thereof
KR20050050111A (ko) 전립선암 및 다른 암의 치료 방법 및 조성물
EP2475367A1 (en) NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES
JP2016510327A (ja) p53再活性化のためのオリゴオキソピペラジン
WO2022026648A1 (en) Inhibition of incexact1 to treat heart disease
KR102185966B1 (ko) Otub1 억제제를 유효성분으로 함유하는 항암 약제의 항암 효과 증진용 약학 조성물 및 이를 이용한 항암 효과 증진방법
CN114729363A (zh) Il-34反义剂及其使用方法
WO2025054596A2 (en) Inhibin subunit beta e-related double stranded oligonucleotide compositions and methods relating thereto
KR20070088706A (ko) 암세포 특이적 세포증식 억제제
WO2023097251A1 (en) Oligonucleotide-containing transcription factor targeting chimeras
US20190055553A1 (en) Methods for identifying and targeting non-coding rna scaffolds
WO2015077693A2 (en) Use of microrna 146-a in the diagnosis, treatment and prevention of picornavirus infection and microran 146-a antagonists
WO2024076967A1 (en) Compositions and methods for treating or preventing nonalcoholic steatohepatitis (nash), anorexia, depression, endometriosis, and other diseases or disorders
US20250375465A1 (en) Methods for affecting tissue-resident t cells
RU2847121C2 (ru) Композиции на основе олигонуклеотидов и способы, связанные с ними
CN109136224A (zh) miR-221/222及其抑制剂用于制备调控肝脂肪沉积、肝纤维化和肝细胞癌的药物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230814

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241227

Comment text: Request for Examination of Application